Aditxt, Inc.
Aditxt, Inc.
Your view on ADTX
Overview
What the company does, where it operates, and who runs it.
About Aditxt, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Amro A. Albanna
- Headquarters
- 737 North Fifth Street, Mountain View, VA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Amro A. Albanna
- Headquarters
- 737 North Fifth Street, Mountain View, VA, US
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming.
It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues.
The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University.
The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
Fair value for Aditxt, Inc. from FRC's valuation model, read against the market price. ADTX last traded at $0.0005; the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Aditxt, Inc.. Starting points for Aditxt, Inc.: EPS -$2575.18, beta 0.93 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Aditxt, Inc.. Aditxt, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Aditxt, Inc.. Trailing twelve-month EPS for Aditxt, Inc. stands at -$2575.18. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
1-Year Price Target
Low
$1,280.00
Median
$1,280.00
High
$1,280.00
Average target
Analyst Ratings
- Strong Buy0
- Buy1
- Hold1
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrJun 2026 | Next QtrSep 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | -$224,553,600,000.00 | -$24,408,000,000.00 | -$22,828,802,400.00 | -$23,216,889,600.00 |
| Low estimate | -$224,553,600,000.00 | -$24,408,000,000.00 | -$22,828,802,400.00 | -$23,216,889,600.00 |
| High estimate | -$224,553,600,000.00 | -$24,408,000,000.00 | -$22,828,802,400.00 | -$23,216,889,600.00 |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago EPS | -$3.45 | -$548.78 | -$1,153.83 | — |
| Growth | -6508799999900.0% | -4447683853.5% | -1978523807.3% | — |
Revenue Estimate
| Revenue | Current QtrJun 2026 | Next QtrSep 2026 | Current YearFY Dec 2026 | Next YearFY Dec 2027 |
|---|---|---|---|---|
| Avg. estimate | $1.00M | $1.00M | $1.26M | $1.32M |
| Low estimate | $1.00M | $1.00M | $1.26M | $1.32M |
| High estimate | $1.00M | $1.00M | $1.26M | $1.32M |
| No. of analysts | 1 | 1 | 1 | 1 |
| Year-ago revenue | $1004.00 | $748.00 | $3195.00 | — |
| Growth | +99501.6% | +133589.8% | +39336.6% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from Benzinga; as of Nov 12, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Aditxt, Inc.. Aditxt, Inc. has reported as a listed company since 2020. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Aditxt, Inc. valued side by side against its closest peers. Aditxt, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Insider Trading
Recent buying and selling by company executives.
Buying and selling by Aditxt, Inc. executives and directors. Shares of Aditxt, Inc. have traded between $4.01 and $11949.75 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Aditxt, Inc.. Coverage tracks Aditxt, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Aditxt, Inc.